GSK3A and Down syndrome: Although no approved treatment currently exists for CTNNB1 syndrome, several potential therapeutic approaches have been proposed, such as using lithium (Stambolic et al. 1996) or GSK-3α/β inhibitors (Mao et al. 2009; Alexander et al. 2024) to modulate β-catenin/Wnt signaling.